EGFR and hepatocellular carcinoma: It was shown that the sorafenib-induced HIF1α- to HIF2α switch resulted in activation of the TGFα/EGFR pathway, and the EGFR inhibitor gefitinib could synergize with sorafenib to induce apoptosis in hypoxic HCC cells [158].